Please assess the completion status of the following clinical trial:

Trial Title: A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Main cohort: Aged ≥2 years to \<11 years (up to the day before 11th birthday inclusive) at time of enrollment; or exploratory cohort: aged ≥3 months to \<2 years (up to the day before 2nd birthday inclusive) at time of enrollment~* Documented, confirmed genetic diagnosis of achondroplasia from historical medical records prior to entry into this trial (test must have been performed at a laboratory fully accredited for genetic testing under local regulations).~* Completed the C4181001 natural history study with at least 2 valid height/length measurements (at least 3 months apart) prior to enrollment in this study. One of these measurement timepoints must be within the 3 months prior to enrollment in C4181005.~* Tanner stage 1 based on investigator assessment during physical examination (must include assessment of breast development for females, testicular stage for males).~* Able to stand independently for height measurements (if ≥2 years of age at enrollment).~* If aged \<2 years at enrollment, has a documented historical MRI brain/cervical spine performed in the previous 12 months.~Exclusion Criteria:~* Presence of co-morbid conditions or circumstances that, in the opinion of the investigator, would affect interpretation of growth data or ability to complete the trial procedures.~* Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.~* Presence of severe obesity (BMI \>95th percentile on Hoover-Fong BMI charts) \[Hoover-Fong et al, 2008\].14~* Known closure of long bone growth plates (cessation of height growth).~* Body weight \<7 kg or \>30 kg.~* Moderate or severe renal impairment CrCL GFR \<60 mL/min/1.73m2 (Calculated GFR based on updated bedside Schwartz formula for pediatric patients (CrCL (mL/min/1.73 m2) = 0.413 \* Height (cms)/ Serum cr (mg/dL) or hepatic impairment (AST/ALT \>1.5 ULN).~* History of hypersensitivity to study intervention or any excipients.~* History of any prior treatment with human growth hormone or related products (including insulin-like growth factor 1 \[IGF-1\]).~* History of receipt of any treatment that are known to potentially affect growth (including oral steroids \>5 days in the last 6 months, high dose inhaled corticosteroids (\>800 mcg/day beclametasone equivalent) and medication for attention deficit hyperactivity disorder).~* History of limb lengthening surgery (defined as distraction osteogenesis/Ilizarov/callostasis technique following submetaphyseal osteotomy to extend bone length).~* Any limb lengthening/corrective orthopaedic surgery planned at any point during the trial period.~* Less than 6 months since fracture or surgical procedure of any bone determined from the screening visit date.~* Presence of any internal guided growth plates/devices.~* History of removal of internal guided growth plates/devices within less than 6 months.~* History of receipt of any investigational product for achondroplasia or that may affect growth/interpretation of growth parameters.~* History of receipt of an investigational product (not for achondroplasia/growth affecting) within the last 30 days or 5 half-lives (whichever is longer).

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Low Dose (Type: EXPERIMENTAL): Low Dose
- Medium Dose (Type: EXPERIMENTAL): Medium Dose
- High Dose (Type: EXPERIMENTAL): High Dose
- PK Phase 2 Formulation (Type: EXPERIMENTAL): Phase 2 formulation \[process 1c\] 3mg/kg
- PK Phase 3 Formulation (Type: EXPERIMENTAL): Phase 3 formulation \[process 2\] 3mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).